A Hong Kong court has granted further leniency to a senior Immigration Department assistant, placing him on a one-year probation order after he was convicted of repeatedly choking his wife and young son during domestic disputes. Kowloon City Court heard on Wednesday that the 49-year-old defendant, identified as “ATK”, preferred probation to community service because he would lose his job and the s...
A Hong Kong court has granted further leniency to a senior Immigration Department assistant, placing him on a one-year probation order after he was convicted of repeatedly choking his wife and young son during domestic disputes. Kowloon City Court heard on Wednesday that the 49-year-old defendant, identified as “ATK”, preferred probation to community service because he would lose his job and the substantial pension accumulated more than 30 years in the disciplined services. He earlier admitted...
Following the death of Ricky Hatton, families and former champions tell a new BBC documentary the sport has not filled the void in care for its fighters.
Following the death of Ricky Hatton, families and former champions tell a new BBC documentary the sport has not filled the void in care for its fighters.
Earnings Call Insights: MaxCyte (MXCT) Q4 2025 Management View Maher Masoud, President, CEO & Executive Director, highlighted that 2025 was a challenging year but also one of "meaningful progress for MaxCyte." The company acquired SeQure DX, integrated the business, and launched the ExPERT DTx platform. Masoud stated, "We made meaningful changes to rightsize spending and strategically improve our ...
Earnings Call Insights: MaxCyte (MXCT) Q4 2025 Management View Maher Masoud, President, CEO & Executive Director, highlighted that 2025 was a challenging year but also one of "meaningful progress for MaxCyte." The company acquired SeQure DX, integrated the business, and launched the ExPERT DTx platform. Masoud stated, "We made meaningful changes to rightsize spending and strategically improve our operations. And most recently, we launched a new product into ExPERT DTx that will allow us to work with developers earlier in research and filament discovery." Masoud reported $33 million of total revenue for the full year, including $29.6 million of core revenue and $3.4 million of strategic Platform License Program revenue. He noted the installed instrument base grew to 857 units from 760 at the end of 2024. The ExPERT DTx launch targets earlier-stage research and drug discovery, offering a modular 96-well electroporation platform designed to streamline workflows and facilitate progression from discovery to GMP-compliant manufacturing. Masoud outlined 2026 revenue guidance: "we expect total revenue to be in the range of $30 million to $32 million, consisting of $25 million to $27 million of core revenue and $5 million of SPL program-related revenue." He acknowledged a $4 million core revenue headwind from SPL customer program rationalization and a recent license termination, stating, "we expect Q1 to be our lightest quarter for core revenue with the back half weighted year." The CEO emphasized an ongoing commitment to innovation and a belief that "the headwinds facing our business are a result of the conservation of capital by biotechs... which we expect to stabilize in the second half of 2026." On management changes, Masoud announced, "Parmeet Ahuja will be joining MaxCyte as Chief Financial Officer, succeeding Doug Swirsky effective March 30." CFO Douglas Swirsky reported, "Total revenue for the full year was $33 million compared to $38.6 million in 2024, representing ...